Myung In Pharmaceutical LTD. (KRX:317450)

South Korea flag South Korea · Delayed Price · Currency is KRW
56,700
+500 (0.89%)
At close: Apr 29, 2026
Market Cap820.52B
Revenue (ttm)287.25B +6.6%
Net Income81.44B +18.6%
EPS6,718.00 +9.6%
Shares Out14.60M
PE Ratio8.37
Forward PEn/a
Dividend1,500.00 (2.67%)
Ex-Dividend DateDec 29, 2025
Volume14,234
Average Volume20,577
Open56,900
Previous Close56,200
Day's Range55,900 - 56,900
52-Week Range52,000 - 134,500
Betan/a
RSI48.00
Earnings DateApr 14, 2026

About KRX:317450

Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides APIs, such as benztropine mesylate, benidipine hcl, clopidogrel bisulfate... [Read more]

Industry Pharmaceutical Preparations
Founded 1985
Employees 335
Stock Exchange Korea Stock Exchange
Ticker Symbol 317450
Full Company Profile

Financial Performance

In 2025, KRX:317450's revenue was 287.25 billion, an increase of 6.61% compared to the previous year's 269.43 billion. Earnings were 81.44 billion, an increase of 18.59%.

Financial Statements